Skip to content

Redefine

what's possible

See what’s next in managing your patients’ vision care needs with advanced VTI contact lens technology.

Take your
patients and practice
further with VTI innovation

For those who’ve experienced it, you know NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses redefine vision for presbyopes and help you take control of paediatric myopia. With Neurofocus Optics® technology, these lenses offer crisp, clear vision at all distances1 and demonstrate a 96% decrease in the rate of myopia progression.2

Enhanced Multifocal for Myopia Progression Control

Featuring Patented Neurofocus Optics® Technology with an extended depth of focus (EDOF), centre distance design.1

Enhanced Multifocal for Presbyopia

NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses create an extended depth of focus to deliver a wider range of clear vision—unlike single vision or traditional multifocal lenses.1

Become a
certified fitter

Getting started with NaturalVue® Multifocal contact lenses has never been easier.

Focal Points

See the latest news about VTI and the vision care industry.

NaturalVue® Multifocal Wins The Contact Lens Award for 2024

Celebrating Excellence in the UK Optical Industry

Defocus Press Release

VTI Releases Defocus Curve Data Evaluating the Functional Visual Range of the NaturalVue® Enhanced Multifocal EDOF Design for Presbyopia

PROTECT Press Release

VTI Continues Release of 1-Year Data from the Ongoing PROTECT Clinical Trial for Myopia Progression Control at the Global Specialty Lens Symposium

PROTECT Press Release

VTI Announces Positive Interim 1-Year Data from the PROTECT Clinical Trial for Myopia Progression Control at the American Academy of Optometry Annual Meeting

Aragón Named VTI CEO and Executive Director

Dr. Juan Carlos Aragón named as VTI’s Chief Executive Officer and Executive Director

MyPath Initiative Launched

VTI Launches the MyPath Myopia Education Initiative: The Path to Success in the Management of Myopia

6-Year Data Released

6-Year Myopia Progression Data for NaturalVue®  Multifocal Announced at American Academy of Optometry’s Annual Meeting

New CMO Appointed

Visioneering Technologies, Inc. Appoints Ashley Tuan, OD, PhD as Chief Medical Officer

Visioneering Technologies Unveils New NaturalVue® Enhanced Multifocal

The Enhanced Multifocal 1 Day™ Contact Lenses feature the TripleTear™ Lubrication System and a new Ultra-Tapered Edge

VTI/NaturalVue PFAS Statement

VTI has Confirmed with its Manufacturer that no NaturalVue Soft Contact Lenses are Formulated with Fluorinated Polymers or PFAS

7 New Markets Launched

Visioneering Technologies Launches New NaturalVue® Enhanced Multifocal in 7 Markets Simultaneously

6-Year Data Published

Visioneering Technologies Announces Publication of Peer-Reviewed Data from a 6-Year Myopia Progression Study in Clinical Ophthalmology

Enrollment Milestone

Visioneering Achieves 50% Enrollment Milestone in its PROTECT International Clinical Study for Myopia Progression Control

#GameOverMyopia

As video game use increases, the Global Myopia Awareness Coalition brings its message to gamers.

Global Expansion

VTI enters European sales and distribution agreement with Menicon, Japan’s largest contact lens company.

Educational Series

The first installment discusses treatment of children in clinical practice and features insights from world leading researchers and clinicians.

VTI UNVEILS NATURALVUE® SPHERE WITH COMFORT ENHANCERS

Clinical study shows new CleanComfort® technology provides more comfortable lens wear morning and night.

VTI LAUNCHES NATURALVUE® MULTIFOCAL CONTACT LENSES IN PLUS POWERS

Company now provides most expansive parameter range of any daily disposable multifocal.1

AWARD OF EXCELLENCE

Visioneering wins Award of Excellence for its NaturalVue® Multifocal 1 Day Contact Lenses at Australia’s largest eyecare event.

VTI SPONSORS

Visioneering Technologies, Inc., Sponsors “The Truth about Myopia – Part 2.”

VTI CONTINUES EXPANSION

Visioneering continues Asia expansion with registration achieved in Singapore.